• Savara highlighted new exercise performance findings from the double-blind phase of its IMPALA-2 Phase 3 trial of inhaled molgramostim in autoimmune pulmonary alveolar proteinosis, with results already presented in an oral session at the American Thoracic Society International Conference 2026.
• Patients receiving molgramostim showed better functional performance on treadmill testing than those on placebo, pointing to improved ability to sustain activity.
• The readout adds supportive evidence to the drug’s overall efficacy profile in the study, strengthening the case for potential real-world benefit in this rare lung disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605181455BIZWIRE_USPR_____20260518_BW925976) on May 18, 2026, and is solely responsible for the information contained therein.